Why is Glaxosmi. Pharma falling/rising?

As of 24-Sep, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,749.50, which reflects a decrease of 10.35 points or 0.38%. The stock has been losing value for the last two days, with a total drop of 0.42% during this period. It has traded within a narrow range of Rs 20.35, and the delivery volume has significantly decreased by 44.18% compared to the 5-day average, indicating falling investor participation. Despite a high management efficiency with a return on equity (ROE) of 42.32% and a low debt-to-equity ratio, these positive factors have not been sufficient to counteract the recent downward price movement.
In the broader market context, the stock's performance over the past week shows a modest increase of 0.51%, while the benchmark Sensex has declined by 1.18%. However, over the past month, Glaxosmithkline's stock has underperformed with a decrease of 1.35%, contrasting with the Sensex's slight gain of 0.50%. Year-to-date, the stock has outperformed the benchmark significantly, with a return of 22.38% compared to the Sensex's 4.58%. This suggests that while the stock has had a strong performance overall, recent trends indicate challenges that may be affecting investor confidence and participation.